Cover Image
市場調查報告書

新加坡及馬來西亞的IVD

IVD in Singapore and Malaysia

出版商 Kalorama Information 商品編碼 294355
出版日期 內容資訊 英文 200 Pages
訂單完成後即時交付
價格
Back to Top
新加坡及馬來西亞的IVD IVD in Singapore and Malaysia
出版日期: 2014年01月01日 內容資訊: 英文 200 Pages
簡介

東南亞向包含醫療提供者與體外診斷(IVD)產業的各種產業供應商展示獨特的機會。IVD企業經由新加坡以及吉隆坡,使用約3500萬人潛在患者、年度70萬人醫療旅遊,及東南亞(或除了日本、澳洲,以及韓國的東南亞以外的亞洲)那裡每人的高支出醫療制度。

本報告提供新加坡及馬來西亞的體外診斷(IVD)市場相關調查、各國的醫療統計、重要醫院、實驗室市場及主要市場區隔市場相關資料、新加坡、馬來西亞市場的跨國公司簡介,為您概述為以下內容。

第1章 簡介

  • 新加坡、馬來西亞的IVD市場
  • 新加坡的醫療制度
  • 新加坡人的健康狀態
  • 新加坡的IVD產品的法規
  • 馬來西亞的醫療制度
  • 馬來西亞人的健康狀態
  • 馬來西亞的IVD產品的法規

第2章 IVD市場分析

  • 臨床化學
  • 微生物學、ID/AST及分子
  • 醫護檢查站
  • 免疫檢測法
  • 尿液檢查
  • 分子檢驗
  • 凝結
  • 組織學
  • 血液學
  • 血液檢驗、分型
  • 流式細胞技術
  • 新加坡、馬來西亞的IVD整體市場

第3章 IVD企業、市場領導

  • Abbott Laboratories (Singapore) Pte Ltd.
  • Beckman Coulter Singapore Pte Ltd.
  • Becton Dickinson Medical (Singapore) Pte Ltd.
  • Bio-Rad Laboratories (Singapore) Pte Ltd.
  • bioMerieux Singapore Pte Ltd.
  • Life Technologies Holdings Pte Ltd.
  • Roche Diagnostics Asia Pacific Pte Ltd.
  • Siemens Healthcare Diagnostics Pte Ltd.
  • Sysmex Asia Pacific Pte Ltd.
  • Affymetrix Singapore Pte Ltd.
  • ClearBridge BioLoc Pte Ltd.
  • ClearBridge BioMedics Pte Ltd.
  • Innogene Kalbiotech Pte Ltd.
  • MP Biomedicals Asia Pacific Pte Ltd.
  • PathGEN Dx Pte Ltd.
  • Sentec Pte Ltd.
  • Vela Diagnostics
  • Volition Pte Ltd.

圖表

目錄
Product Code: KLI5177833

IVD manufacturers seeking marginal growth are focusing on regional markets. The whole of Southeast Asia represents a unique opportunity for healthcare providers and their various industry suppliers, including the in vitro diagnostics (IVD) industry. In this report, Kalorama details two nations that are expected to provide opportunity for IVD manufacturers: Singapore and Malaysia.

The nexus of regional trade, and a leading port and center for the entire Asia-Pacific, is Singapore. The city-state features the most developed and highest rated healthcare system in Southeast Asia and serves as the headquarters and regional manufacturing center for some medical device, biotechnology, IVD, and pharmaceutical companies. Its neighbor Malaysia, an upper middle-income nation has arguably the second-most developed healthcare system in Southeast Asia. Through Singapore or Kuala Lumpur, IVD companies have access to approximately 35 million potential patients, over 700,000 annual medical tourists, and healthcare systems with higher per capita spending than anywhere else in Southeast Asia or anywhere in Asia outside of Japan, Australia, or Korea. Singapore and Malaysia present IVD markets and opportunities with healthy prospects and solid fundaments in clinical demand.

This Kalorama Information Report, IVD in Singapore and Malaysia contains the following data:

  • Healthcare Statistics for Singapore and Malaysia
  • Significant Hospitals in Both Countries
  • The Lab Market in Singapore and Malaysia
  • Markets for Key Segments Clinical Chemistry, Microbiology - ID/AST, Microbiology - Molecular, PointofCare - OTC Diabetes, PointofCare - OTC Other, PointofCare- Professional, Immunoassays - Infectious Disease, Immunoassays - Other, Urinalysis, Molecular Diagnostics, Coagulation, Histology, Hematology, Blood Testing and Typing, Flow Cytometry)

Multinational companies participate in the Singaporean and Malaysian market. Among those companies profiled in this report are the following:

  • Abbott Laboratories (Singapore) Pte Ltd.
  • Beckman Coulter Singapore Pte Ltd.
  • Becton Dickinson Medical (Singapore) Pte Ltd.
  • Bio-Rad Laboratories (Singapore) Pte Ltd.
  • bioMérieux Singapore Pte Ltd.
  • Life Technologies Holdings Pte Ltd.
  • Roche Diagnostics Asia Pacific Pte Ltd.
  • Siemens Healthcare Diagnostics Pte Ltd.
  • Sysmex Asia Pacific Pte Ltd.

Table of Contents

CHAPTER ONE: INTRODUCTION

  • The IVD Markets of Singapore and Malaysia
  • Singaporean Healthcare System
  • How Health Care Functions in Singapore - Subsidies, Medisave,
  • MediShield, Medifund and Private Payments
  • Government Funding Programs - Medisave, MediShield and Medifund
  • Subsidized Care
  • Private Payments - Out-of-Pocket, Employer Benefits, Private Insurance
  • Healthcare Infrastructure in Singapore - Hospitals, Clinics, and Private Labs

Health Status of Singaporeans

  • IVD Product Regulation in Singapore
  • Malaysian Healthcare System
  • How Health Care Functions in Malaysia - Universal Healthcare System and Private Payment
  • Universal Healthcare System
  • Private Payments
  • Healthcare Infrastructure in Malaysia - An Overview of Clinics,
  • Hospitals, and Private Labs

Health Status of Malaysians

  • IVD Product Regulation in Malaysia

CHAPTER TWO: IVD MARKET ANALYSIS

  • Clinical Chemistry
  • Microbiology, ID/AST and Molecular
  • Point of Care Testing
  • Immunoassays
  • Urinalysis
  • Molecular Testing
  • Coagulation
  • Histology
  • Hematology
  • Blood Testing and Typing
  • Flow Cytometry
  • Total IVD Markets In Singapore and Malaysia

CHAPTER THREE:- IVD COMPANIES AND MARKET LEADERS

  • Abbott Laboratories (Singapore) Pte Ltd.
  • Beckman Coulter Singapore Pte Ltd.
  • Becton Dickinson Medical (Singapore) Pte Ltd.
  • Bio-Rad Laboratories (Singapore) Pte Ltd.
  • bioMérieux Singapore Pte Ltd.
  • Life Technologies Holdings Pte Ltd.
  • Roche Diagnostics Asia Pacific Pte Ltd.
  • Siemens Healthcare Diagnostics Pte Ltd.
  • Sysmex Asia Pacific Pte Ltd.
  • Affymetrix Singapore Pte Ltd.
  • ClearBridge BioLoc Pte Ltd.
  • ClearBridge BioMedics Pte Ltd.
  • Innogene Kalbiotech Pte Ltd.
  • MP Biomedicals Asia Pacific Pte Ltd.
  • PathGEN Dx Pte Ltd.
  • Sentec Pte Ltd.
  • Vela Diagnostics
  • Volition Pte Ltd.

CHAPTER ONE: INTRODUCTION

  • Figure 1-1: Singaporean and Malaysian IVD Markets
  • Figure 1-2: Healthcare Spending in Singapore, Malaysia and Comparative Countries - OECD, Asia-Pacific, Emerging Economies (2011 Total Health Expenditure in Per Capita 2005 PPP Dollars and % of GDP)
  • Figure 1-3: Singapore Public Hospital Directory
  • Table 1-3: Singapore Private Hospital Directory
  • Figure 1-4: Singapore Medical Lab Testing Breakout - Hospitals, Hospital Lab Testing Services, Private Lab / Community Pathology (% of Testing by Value)
  • Table 1-4: Singaporean Market Private Labs - Company Directory
  • Figure 1-5: Mortality Rate of Singaporeans and OECD Averages (Deaths per 100,000 population for Coronary Heart Disease, Stroke, Cancer, COPD, Diabetes)
  • Figure 1-6: Key Adult Singaporean Health Metrics (Hypertension, Diabetes, High Cholestrol, Obesity, Smoker, Asthma, Perceived Health)
  • Table 1-5: Selected Infectious Disease Incidence Rates (per 100,000 population) - Singapore, Australia, United States, EU/EEA (Viral Hepatitis, Salmonellosis, Typhoid Fever, Dengue, Malaria, Bacterial Meningitis, Tuberculosis)
  • Figure 1-7: Total Population of Malaysia, 2008-2020 (millions)
  • Figure 1-8: Healthcare Expenditure by Payer and Program In Malaysia (%)
  • Table 1-6: Malaysian Clinic Survey of Laboratory Capabilities - Dedicated Clinic Lab Space, In- House Lab Services, Out-Sourced Lab Services (% of Private and Public Primary Care Clinics)
  • Table 1-7: Malaysian Clinic Survey of Medical Devices/IVD Instruments - Hemoglobin (HbA1c) Analyzer, Chemistry Analyzer, Hematology Analyzer, Bilirubinometer, Ultrasound, X-Ray (% of Clinics w/ Installed, Private/Public)
  • Table 1-8: High-Technology or IVD Client Indicators for Malaysian Hospitals - CT Scan, MRI, PET Procedure Volumes; Hospitals Providing General Surgical Services and with ICUs (Private / Public Hospitals)
  • Table 1-9: Malaysian Market Private Labs - Company Directory
  • Figure 1-9: Mortality Rate of Malaysians and OECD Averages (Deaths per 100,000 population for Communicable Disease and Infection, Coronary Heart Disease, Stroke, Cancer, Chronic Respiratory Disease, Diabetes)
  • Figure 1-10: Key Malaysian Health Metrics (Hypertension, Diabetes, High Cholestrol, Obesity, Smoker)
  • Table 1-10: Selected Infectious Disease Incidence Rates (per 100,000 population) - Malaysia, Singapore, United States, EU/EEA (Viral Hepatitis, Salmonellosis, Typhoid Fever, Dengue, Malaria, Bacterial Meningitis, Tuberculosis)

CHAPTER TWO: IVD MARKET ANALYSIS

  • Figure 2-1: Singapore and Malaysia Clinical Chemistry Markets
  • Figure 2-2: Singapore and Malaysia Microbiology Markets (ID/AST, Molecular)
  • Figure 2-3: Singapore and Malaysia Point of Care Testing (POCT) Markets (Professional, OTC Diabetes, OTC Other)
  • Figure 2-4: Singapore and Malaysia Immunoassay Markets (Infectious Disease, Other)
  • Figure 2-5: Singapore and Malaysia Urinalysis Markets
  • Figure 2-6: Singapore and Malaysia Molecular Diagnostics Markets
  • Figure 2-7: Singapore and Malaysia Coagulation Markets
  • Figure 2-8: Singapore and Malaysia Histology/Cytology Markets
  • Figure 2-9: Singapore and Malaysia Hematology Markets
  • Figure 2-10: Singapore and Malaysia Blood Testing and Typing Market
  • Figure 2-11: Singapore and Malaysia Flow Cytometry Markets
  • Table 2-1: IVD Market in Singapore by Segment (Clinical Chemistry, Microbiology - ID/AST, Microbiology - Molecular, PointofCare - OTC Diabetes, PointofCare - OTC Other, PointofCare- Professional, Immunoassays - Infectious Disease, Immunoassays - Other, Urinalysis, Molecular Diagnostics, Coagulation, Histology, Hematology, Blood Testing and Typing, Flow Cytometry)
  • Table 2-2: IVD Market in Malaysia by Segment (Clinical Chemistry, Microbiology - ID/AST, Microbiology - Molecular, PointofCare - OTC Diabetes, PointofCare - OTC Other, PointofCare- Professional, Immunoassays - Infectious Disease, Immunoassays - Other, Urinalysis, Molecular Diagnostics, Coagulation, Histology, Hematology, Blood Testing and Typing, Flow Cytometry)
  • Table 2-3: Combined Singapore-Malaysia IVD Market by Segment (Clinical Chemistry, Microbiology - ID/AST, Microbiology - Molecular, PointofCare - OTC Diabetes, PointofCare - OTC Other, PointofCare- Professional, Immunoassays - Infectious Disease, Immunoassays - Other, Urinalysis, Molecular Diagnostics, Coagulation, Histology, Hematology, Blood Testing and Typing, Flow Cytometry)

CHAPTER THREE: SINGAPORE AND MALAYSIA - IVD COMPANIES AND MARKET LEADERS

  • Table 3-1: Singapore and Malaysia IVD Market Leaders
Back to Top